statistiche ricercatore

Nazione	#
US - Stati Uniti d'America	519
SG - Singapore	199
SE - Svezia	88
BR - Brasile	83
CN - Cina	62
IT - Italia	51
DE - Germania	39
FR - Francia	38
VN - Vietnam	36
IN - India	34
IE - Irlanda	23
GB - Regno Unito	18
ID - Indonesia	14
AR - Argentina	12
JP - Giappone	8
RU - Federazione Russa	7
CA - Canada	6
KR - Corea	6
MX - Messico	6
ZA - Sudafrica	6
HK - Hong Kong	5
MA - Marocco	4
NL - Olanda	4
AT - Austria	3
BD - Bangladesh	3
FI - Finlandia	3
PK - Pakistan	3
PL - Polonia	3
SA - Arabia Saudita	3
UZ - Uzbekistan	3
VE - Venezuela	3
BO - Bolivia	2
IQ - Iraq	2
JO - Giordania	2
LT - Lituania	2
PA - Panama	2
PH - Filippine	2
PS - Palestinian Territory	2
PT - Portogallo	2
AM - Armenia	1
AZ - Azerbaigian	1
BE - Belgio	1
CH - Svizzera	1
CL - Cile	1
CR - Costa Rica	1
CZ - Repubblica Ceca	1
DK - Danimarca	1
DM - Dominica	1
DZ - Algeria	1
ET - Etiopia	1
GE - Georgia	1
GR - Grecia	1
HR - Croazia	1
IL - Israele	1
IR - Iran	1
JM - Giamaica	1
KZ - Kazakistan	1
LK - Sri Lanka	1
MM - Myanmar	1
NP - Nepal	1
PE - Perù	1
RO - Romania	1
RS - Serbia	1
SK - Slovacchia (Repubblica Slovacca)	1
SV - El Salvador	1
SY - Repubblica araba siriana	1
TR - Turchia	1
TT - Trinidad e Tobago	1
UA - Ucraina	1
Totale	1.338

Nome	#
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases	159
Public investment trends across levels of government in Italy	129
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study	125
SF3B1-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation	119
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials	117
Comparison between sedation room and operating room in central venous catheter positioning in children	116
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study	113
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases	106
CD49d promotes disease progression in chronic lymphocytic leukemia: New insights from CD49d bimodal expression	102
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab	95
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia	89
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study	84
Totale	1.354

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	1	0	0	0	0	0	0	0	0	0	0	0	1
2021/2022	142	0	0	35	22	18	3	2	17	6	2	27	10
2022/2023	220	29	31	17	31	10	30	11	15	32	0	11	3
2023/2024	132	6	25	6	9	11	45	3	7	1	4	5	10
2024/2025	266	5	4	15	13	18	10	12	8	32	57	52	40
2025/2026	575	104	23	40	53	91	34	90	32	41	31	32	4
Totale													1.354

IRIS UniCatt